Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Karen Hunke

Nurse Practitioner, Family Ames, IA Nurse Practitioner

NPI 1487648705 CMS profile 10997552

2010 Philadelphia St, Suite 1, Ames, IA 50010

Open in the dashboard

General payments

$20,253

492 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karen Hunke of Ames, IA is reported in the CMS Open Payments database as having received $20,253 across 492 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,560 81
2024 General $3,339 96
2023 General $2,728 127
2022 General $4,156 96
2021 General $7,471 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karen Hunke
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Karen Hunke were reported at $2,560. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Karen Hunke Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $7,471 $124 $35–$379 $132
2022 $4,156 $141 $44–$430 $149
2023 $2,728 $154 $49–$476 $160
2024 $3,339 $165 $51–$504 $164
2025 $2,560 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $5,487 47 payments
  2. AbbVie, Inc. $4,092 111 payments
  3. UCB, Inc. $3,592 62 payments
  4. Janssen Biotech, Inc. $1,635 31 payments
  5. Novartis Pharmaceuticals Corporation $1,316 24 payments
  6. Sun Pharmaceutical Industries Inc. $742 30 payments
  7. E.R. Squibb & Sons, L.L.C. $628 31 payments
  8. Amgen Inc. $480 35 payments
  9. Regeneron Healthcare Solutions, Inc. $373 13 payments
  10. Galderma Laboratories, L.P. $333 25 payments
  11. Other $1,575 83 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,018 464 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,263 12 payments
  3. Consulting Fee $3,373 3 payments
  4. Education $600 13 payments
Products named General payments · program years 2021–2025
  1. TALTZ $5,258 39 payments
  2. SKYRIZI $1,809 64 payments
  3. HUMIRA $1,720 18 payments
  4. TREMFYA $1,614 29 payments
  5. Bimzelx $1,051 28 payments
  6. COSENTYX $873 8 payments
  7. SOTYKTU $620 30 payments
  8. Cimzia $516 29 payments
  9. ILUMYA $495 27 payments
  10. Otezla $480 35 payments
  11. Other $4,330 225 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

596

Median for Nurse Practitioner: 389

Drug cost

$799,201

Median for Nurse Practitioner: $21,885

Branded share of claims

21%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 12 $289,007
Humira(Cf) Pen Adalimumab Brand 18 $265,168
Dupixent Pen Dupilumab Brand 44 $170,923
Otezla Apremilast Brand 26 $56,966
Betamethasone Dipropionate Generic 88 $4,205
Tacrolimus Generic 35 $3,226
Fluorouracil Generic 23 $1,976
Doxycycline Hyclate Generic 73 $1,730
Clindamycin Phosphate Generic 29 $1,484
Cimetidine Generic 19 $1,212

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$64,581

Of which drugs: $25

Medicare patients

345

Average age 74

Services billed

2,203

192 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 35%
Chronic kidney disease 24%
Diabetes 21%
Ischemic heart disease 21%
Osteoporosis 17%
Depression 16%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 51 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $1,042
$1,042 — —
Bimzelx
  • UCB, Inc. $644
$644 — —
SKYRIZI
  • AbbVie, Inc. $276
$276 12 —
OLUMIANT
  • Lilly USA, LLC $205
$205 — —
RINVOQ
  • AbbVie, Inc. $193
$193 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

492 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record